Loading…
← CockpitCompetitor Analysis › SYNGENE.NS Syngene InternationalOpen in the cockpit ↗

Syngene InternationalSYNGENE.NSCompetitor analysis, valuation and peers

India · INR·Commercial Services›Miscellaneous Commercial Services

Contract research and manufacturing organization (Biocon Group) providing drug discovery and CDMO services to global pharma/biotech.

≈ India's smaller WuXi AppTec/Lonza peer for pharma CRO/CDMO servicesMomentum strong 63
Mkt cap
$1.88B
US dollars, full cap
Free float
47%
of shares outstanding
$/day
$11.6M
20-day average traded
Fwd P/E
70.7×
forward earnings
ROIC−WACC
-8.2 pp
WACC 15.3%
Hurdle
+25 pp
Req g minus delivered
Next earnings
71 days
28 Jan 2027
Close · INR₹434.80
1D+0.1%
1W-1.8%
1M+9.4%
3M+7.6%
6M-7.8%
YTD-33.2%
1Y-34.5%
ATR %3.4%
Beta0.64
52w lowhigh36.0% off high

What Syngene International does

Contract research and manufacturing organization (Biocon Group) providing drug discovery and CDMO services to global pharma/biotech.

Is paid by contract: some clients buy scientists' time by the hour or project, others lease dedicated labs and teams for several years, which makes revenue steadier. Large pharma partners such as Bristol Myers Squibb and Amgen have dedicated research centres there. Biocon, founded by Kiran Mazumdar-Shaw, is the majority shareholder.

In one line: India's smaller WuXi AppTec/Lonza peer for pharma CRO/CDMO services.

Products and services

  • Contract drug discovery/research services
  • Contract development & manufacturing (CDMO)
  • Dedicated R&D centres for large pharma clients

Customers

  • Global pharmaceutical & biotech companies

Where it sits in the supply chain

  • Pharma services
  • Contract research & manufacturing…
  • Drug discovery, development…

What could go right

  • Global pharma outsourcing (CRO/CDMO) growth
  • China+1 sourcing diversification

What could go wrong

  • Client concentration risk (large pharma partners)
  • Regulatory (FDA) inspection/compliance risk

Moat: narrow (process know-how, customer qualification, regulatory licence). Biocon Group backing plus dedicated, long-term R&D partnerships with major global pharma clients.

Headquarters: Bengaluru, India · Founded: 1993 · Employees: 8,376

Named competitors

Syngene International at a glance

Size Syngene International (SYNGENE.NS) is an India Industrials company (Miscellaneous Commercial Services) with a market value of $1.88B, the 395th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹434.80 on 18 Nov 2026.

Performance Over six months the shares fell 7.8%, against -1.2% for the median peer and +3.8% for the India market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue fell 6.0% over the last twelve months (peer median +20.5%); the operating margin is 13.0% (peer median 12.2%).

Valuation It trades at 70.7× forward earnings against a peer median of 20.4× (3rd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.2 points below its cost of capital (15.3% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 96SYNGENE.NS 93
Six months, rebased to 100: Syngene International against the median of its 20 peers (local-currency closes).

Syngene International financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹35.2B₹37.4B₹36.4B₹34.9B₹31.9B
Revenue growth—+3%+4%+9%—
Gross profit₹11.4B₹9.84B₹10.2B₹10.3B₹9.36B
EBITDA₹9.07B₹9.97B₹10.5B₹10.8B₹9.94B
Net income₹1.86B₹3.17B₹4.96B₹5.10B₹4.64B
Free cash flown/a₹6.11B₹4.44B₹6.03B₹3.36B
Capital expendituren/a₹3.68B₹7.70B₹5.11B₹5.18B
Total debt₹5.07B₹4.58B₹5.78B₹5.55B₹8.15B

Quarterly statements and history in the cockpit →

Syngene International competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%+20%002091NSPPSG002310HOFI688813FSL0586IGIL688690HCSG6887960029676257688757TICIPS3015717799SYNGENE.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Syngene International is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×60×002091NSPPSGHOFIFSL0586IGILCHOICEIN688690HCSG688796002967IPSSYNGENE.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Syngene International is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%002091NSPPSG002310FSLIGIL688690HCSG688796002967IPSSYNGENE.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Syngene International is the large dot.

Syngene International competitors and peer comparison

Head to head with its named competitors (SYNGENE.NS vs SAILIFE.NS vs DIVISLAB.NS vs 2359.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Syngene International SYNGENE.NS$1.88B-8%-6%13%70.7×36.4%
SAI Life Sciences SAILIFE.NS$4.07B+59%+16%22%87.2×n/a
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%

How Syngene International compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Syngene International against its 20 peers (data as of 18 Nov 2026)
MeasureSYNGENE.NSPeer medianRank in peer set
1-month return+9.4%-0.1%5th highest of 21
6-month return-7.8%-1.2%9th lowest of 21
Distance from 52-week high-36.0%-28.2%7th lowest of 21
Revenue growth (TTM)-6.0%+20.5%lowest of 19
Operating margin13.0%12.2%10th highest of 20
Forward P/E70.7×20.4×3rd most expensive of 16
Growth the price implies (Req g, 7 yrs)36.4%17.7%most demanding of 13
Growth delivered (Del g)+11.4%+9.7%6th highest of 12
Hurdle (Req g minus delivered)+25.0 pp-10.1 pp2nd most demanding of 12
ROIC minus cost of capital-8.2 pp+1.8 pp4th lowest of 18
EV / EBITDA19.3×13.9×4th most expensive of 11
Net debt / EBITDA-0.0×0.8×5th least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Syngene International SYNGENE.NSIndia$1.88B-8%-6%13%70.7×36.4%+11.4%
Jiangsu Guotai International 002091.SZChina$1.87B-15%+7%6%9.7×-21.2%+5.5%
Insperity NSPUnited States$1.86B+55%+2%0%19.6×19.4%+9.7%
Prosegur Compania de Seguridad PSG.MCSpain$1.82B+10%+4%6%12.2×-3.7%+6.7%
Beijing Orient EcoEnergy 002310.SZChina$1.75B-25%+35%12%n/a36.0%-47.6%
Hoist Finance HOFI.STSweden$1.75B+20%+16%30%12.2×n/an/a
Xi'an Taijin New Energy & Materials Sci-Tech 688813.SSChina$1.73B-42%n/an/an/an/an/a
Firstsource Solutions FSL.NSIndia$2.04B+13%+20%12%20.4×19.2%+13.5%
China Conch Venture 0586.HKHong Kong$1.72B-30%+21%18%5.9×n/an/a
International Gemological Institute IGIL.NSIndia$2.05B+33%+21%58%26.0×16.3%+37.6%
Choice International CHOICEIN.NSIndia$1.70B+8%+34%27%47.6×n/an/a
Suzhou Nanomicro Technology 688690.SSChina$2.08B-1%+26%25%51.5×33.2%+35.2%
Healthcare Services HCSGUnited States$1.69B+21%+4%6%21.3×4.3%+0.9%
Biocytogen Pharmaceuticals (Beijing) 688796.SSChina$2.09B-33%+40%24%73.0×31.0%+41.1%
GRG Metrology & Test 002967.SZChina$1.68B-20%+13%13%22.2×3.6%+14.4%
Sigurd Microelectronics 6257.TWTaiwan$2.10B-28%+18%24%11.3×n/an/a
Wintech Nano (Suzhou) 688757.SSChina$1.67B-22%+23%7%n/an/an/a
TIC Solutions TICUnited States$2.15B+14%+39%-1%n/a32.6%n/a
Ipsos IPS.PAFrance$1.64B-7%+3%12%6.9×-11.2%+6.6%
Teemsun Technology 301571.SZChina$1.64B-1%+61%22%n/an/an/a
Heron Neutron Medical 7799.TWTaiwan$2.15B+56%n/a-5,319%355.2×n/an/a

Questions

Who are Syngene International's main competitors?
Named competitors: SAI Life Sciences (SAILIFE.NS), Divi's Laboratories (DIVISLAB.NS), WuXi AppTec (2359.HK). The cockpit's measured peer set (industry) also includes Jiangsu Guotai International (002091.SZ), Insperity (NSP), Prosegur Compania de Seguridad (PSG.MC), Beijing Orient EcoEnergy (002310.SZ), Hoist Finance (HOFI.ST), Xi'an Taijin New Energy & Materials Sci-Tech (688813.SS).
Is Syngene International expensive compared with its peers?
On forward p/e it trades at 70.7× against a peer median of 20.4×, 3rd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Syngene International stock performed?
Over six months to 18 Nov 2026 the shares returned -7.8% against -1.2% for the median peer; over one year -34.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.